Reports Friday said the European Union collective economy will contract in the fourth quarter of 2012, marketing the third straight quarter of negative growth.
As drug makers struggle to rebound from patent losses on many of their big-selling medicines, can contract research organizations expect to experience some collective growth this year?
Because all grievances that stem from drug-related cases must be handled under the collective bargaining agreement, unlike in a regular breach of contract suit, the employer can not simply single out individualized clauses in the employee agreement as a bonafide legal argument to get out of the contract.